<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053013</url>
  </required_header>
  <id_info>
    <org_study_id>0911010739</org_study_id>
    <nct_id>NCT01053013</nct_id>
  </id_info>
  <brief_title>Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer</brief_title>
  <acronym>Macrobead</acronym>
  <official_title>An Open-Label Phase 2 Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Cell-Containing Agarose-Agarose Macrobeads in the Treatment of Patients With Treatment-Resistant, Metastatic Pancreatic or Colorectal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Rogosin Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Rogosin Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical research study of an investigational (FDA IND-BB 10091) treatment for
      patients with pancreatic cancer (all stages) and advanced colorectal cancer that no longer
      responds to standard therapies.

      The treatment is being evaluated for its effect on tumor growth. It consists of the placement
      (implantation) of small beads that contain mouse renal adenocarcinoma cells (RENCA
      macrobeads). The cells in the macrobeads produce substances that have been shown to slow or
      stop the growth of tumors in experimental animals and veterinary patients. It has been tested
      in 31 human subjects with different types of cancers in a Phase I safety trial. Phase II
      studies in patients with colorectal, pancreatic or prostate cancers are in progress.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">November 2019</completion_date>
  <primary_completion_date type="Actual">November 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor volume and number of metastases</measure>
    <time_frame>16 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Cancer macrobeads</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cancer macrobead placement in abdominal cavity</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cancer macrobead placement in abdominal cavity</intervention_name>
    <description>8 macrobeads per kilogram</description>
    <arm_group_label>Cancer macrobeads</arm_group_label>
    <other_name>cancer macrobeads</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer of pancreas, colon or rectum

          -  Evidence of metastasis

          -  Failed available therapies (pancreatic cancer may be treated without previous
             therapies)

          -  Resolution of any toxic effects of previous therapies

          -  Performance status (ECOG PS) 0-2

          -  Adequate hematologic, coagulation (INR 2-3 max), hepatic and renal function

          -  Life expectancy of at least 6 weeks

          -  For females, a negative pregnancy test

          -  Agrees to contraceptive use while on study if sexually active

          -  Informed consent

        Exclusion Criteria:

          -  Any condition presenting an unacceptably high anesthetic or surgical risk

          -  HIV positive

          -  Cognitive impairment such as to preclude informed consent

          -  Surgical treatment or chemotherapy within three weeks of scheduled macrobead
             implantation or within four weeks of bevacizumab (or similar drugs), or radiation
             therapy within four weeks of scheduled macrobead implantation

          -  Inadequate hematologic, coagulation (INR &gt;3), hepatic, renal function

          -  Hepatic blood flow abnormalities and/or large-volume ascites

          -  Concurrent cancer of any other type except skin cancer (excluding melanoma)

          -  History of allergic reactions to mouse antigens

          -  Active infection, congestive heart failure, unstable angina, serious cardiac
             arrhythmias, psychiatric illness, difficult social situations not permitting reliable
             participation, active bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry H Smith, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>The Rogosin Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College/The Rogosin Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2010</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>macrobead</keyword>
  <keyword>biological</keyword>
  <keyword>mouse cells</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

